Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis.
Zhao S, Ma Y, Liu L, Fang J, Ma H, Feng G, Xie B, Zeng S, Chang J, Ren J, Zhang Y, Xi N, Zhuang Y, Jiang Y, Zhang Q, Kang N, Zhang L, Zhao H.
Zhao S, et al. Among authors: ren j.
Lung Cancer. 2024 Feb;188:107468. doi: 10.1016/j.lungcan.2024.107468. Epub 2024 Jan 3.
Lung Cancer. 2024.
PMID: 38181454
Clinical Trial.